Panbela Therapeutics’ (PBLA) Neutral Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their neutral rating on shares of Panbela Therapeutics (NASDAQ:PBLA – Free Report) in a research report sent to investors on Thursday, Benzinga reports. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($1.63) EPS, Q4 2024 earnings at ($1.61) EPS, FY2024 earnings at ($6.76) EPS, FY2025 earnings at ($4.44) […]
More Stories
Ilhan Omar, Broken Vetting, and Minnesota’s Billion-Dollar Fraud: The Questions That Will Not Die
By Stephen Zogopoulos, USNN World News The federal investigation into Rep. Ilhan Omar’s immigration history and the massive public-benefits fraud...
Democrats Sue Trump Admin Over Bid to Clean Up Voter Rolls
By Zachary Stieber Senate Minority Leader Chuck Schumer (D-N.Y.) and other Democrats have sued the Trump administration over its effort...
Implementing Freight Management Software: In-House or With Specialist Help?
You’ve picked a freight platform. Now you have to get it live without stopping trucks, missing invoices or losing track...
DOGE Illegally Accessed Data on Government Workers: Judge
By Zachary Stieber A federal judge ruled on Oct. 20 that a department aimed at making the government more efficient...
UK Rearrests 2 Men Over Suspected Terror Plot at Air Base
By Jill McLaughlin UK police have rearrested two men, suspected of working for Iran’s intelligence service, for allegedly plotting to...
$245 Million Taxpayer-Backed Loan to Fund Naval Shipbuilding Facilities
By AAP Australia will lend hundreds of millions of dollars to the nation’s largest shipbuilder for a massive new manufacturing...